CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
Androgel (Testosterone Gel) +1 moredrug
Likely dose
Androgel (Testosterone Gel) 5gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01201863
NCT01201863Phase 4Completed

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

Craig Hospital·interventional·Posted Sep 15, 2010·Updated Jul 27, 2021

In Brief

A Phase 4 clinical trial evaluating Androgel (Testosterone Gel) and Placebo gel for Endocrine Dysfunction and 2 related conditions. Completed, enrolled 46 participants across 1 site.

Detailed Summary

The purpose of this study was to address 3 short term objectives; (1) Determine the effects of physiologic testosterone (T) therapy on neurological function and functional independence following traumatic brain injury (TBI) in hypogonadal men during inpatient rehabilitation; (2) Document the natural history of neuroendocrine dysfunction and recovery in men during inpatient rehabilitation after TBI; (3) Obtain data to validate the NIH toolbox, a novel assessment of neurological function for use in the TBI population; and 2 long-term objectives: (1) Utilize study findings to design a multicenter trial to further assess the impact of T therapy in hypogonadal men following TBI and (2) Impact TBI practice management with new information about neuroendocrine dysfunction after TBI and hormone treatments to improve outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2010
Enrollment StartSep 1, 2010
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.8 years ago

Interventions

Androgel (Testosterone Gel)drug

2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.

Placebo gelother

2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.